<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1011372</article-id><article-id pub-id-type="publisher-id">ACM-38505</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201100000_59385340.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  动静脉血栓检测的检验及影像学研究进展
  Research Progress of Laboratory and Imaging Detection of Thrombosis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>婉雯</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>玲</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>姚</surname><given-names>玉宇</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>东南大学心血管研究所，江苏 南京</addr-line></aff><aff id="aff2"><addr-line>东南大学医学院，江苏 南京</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>11</month><year>2020</year></pub-date><volume>10</volume><issue>11</issue><fpage>2463</fpage><lpage>2470</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    血栓栓塞性疾病是当前发病率及病死率较高的心血管系统疾病之一。准确检测血栓的存在是临床工作中的重点问题。传统的血清学、影像学方法结合当前最新的分子技术已经被广泛运用到临床和科研的血栓检测工作中。本文将以血栓形成途径的为基础，对现有的血清学、影像学等检测手段的优缺点以及区别动静脉血栓的方法进行描述，讨论检测动静脉血栓的新方法和分子影像学探针的最新研究进展。
    Thromboembolic disease is one of the most common cardiovascular diseases with high incidence and mortality. And it is a focus of clinical practice to accurately detect the existence of thrombus. The novel molecular technique combined with traditional serological and imaging methods has been widely used in clinical and scientific thrombus detection. On the basis of thrombosis pathway, we describe the advantages of serological and imaging methods, and the methods of distinguishing arteriovenous thrombosis so as to discuss the new methods for the detection of atherothrombosis and venous thrombosis as well as the latest progress of detection methods in molecular probes. 
  
 
</p></abstract><kwd-group><kwd>血栓形成，血清学检测，影像学检测，动静脉血栓的鉴别, Thrombosis</kwd><kwd> Serological Detection</kwd><kwd> Imaging Examination</kwd><kwd> Identification of Artherothrombosis with Venous Thrombosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>血栓栓塞性疾病是当前发病率及病死率较高的心血管系统疾病之一。准确检测血栓的存在是临床工作中的重点问题。传统的血清学、影像学方法结合当前最新的分子技术已经被广泛运用到临床和科研的血栓检测工作中。本文将以血栓形成途径的为基础，对现有的血清学、影像学等检测手段的优缺点以及区别动静脉血栓的方法进行描述，讨论检测动静脉血栓的新方法和分子影像学探针的最新研究进展。</p></sec><sec id="s2"><title>关键词</title><p>血栓形成，血清学检测，影像学检测，动静脉血栓的鉴别</p></sec><sec id="s3"><title>Research Progress of Laboratory and Imaging Detection of Thrombosis<sup> </sup></title><p>Wanwen Chen<sup>1*</sup>, Ling Zhang<sup>1*</sup>, Yuyu Yao<sup>2</sup></p><p><sup>1</sup>School of Medicine, Southeast University, SEU, Nanjing Jiangsu</p><p><sup>2</sup>Institute of Cardiovascular Research, Southeast University, SEU, Nanjing Jiangsu</p><p><img src="//html.hanspub.org/file/6-1571638x4_hanspub.png" /></p><p>Received: Oct. 11<sup>th</sup>, 2020; accepted: Oct. 29<sup>th</sup>, 2020; published: Nov. 5<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/6-1571638x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Thromboembolic disease is one of the most common cardiovascular diseases with high incidence and mortality. And it is a focus of clinical practice to accurately detect the existence of thrombus. The novel molecular technique combined with traditional serological and imaging methods has been widely used in clinical and scientific thrombus detection. On the basis of thrombosis pathway, we describe the advantages of serological and imaging methods, and the methods of distinguishing arteriovenous thrombosis so as to discuss the new methods for the detection of atherothrombosis and venous thrombosis as well as the latest progress of detection methods in molecular probes.</p><p>Keywords:Thrombosis, Serological Detection, Imaging Examination, Identification of Artherothrombosis with Venous Thrombosis</p><disp-formula id="hanspub.38505-formula64"><graphic xlink:href="//html.hanspub.org/file/6-1571638x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/6-1571638x8_hanspub.png" /> <img src="//html.hanspub.org/file/6-1571638x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>不同类型的血栓在起源、形成过程及成分方面有着很大的差别，按照血栓的来源可以将血栓分为动脉血栓和静脉血栓 [<xref ref-type="bibr" rid="hanspub.38505-ref1">1</xref>]。栓体可导致血管闭塞，血栓脱落进入血循环造成栓塞，导致严重的危及生命的事件，如动脉血栓引起心肌梗塞、中风，静脉血栓造成肺栓塞、脑梗死等。动静脉血栓的治疗方法不同 [<xref ref-type="bibr" rid="hanspub.38505-ref2">2</xref>]，利用各类型血栓的组成特点和影像学特征差异进行诊断，可以帮助提高血栓诊断、治疗和检测的效率。并有希望利用这些差异早期筛检或预防血栓性疾病。</p></sec><sec id="s6"><title>2. 动脉血栓和静脉血栓的形成</title><p>大多数动脉血栓的形成是由于粥样硬化斑块的破裂和血管内皮的损伤。血管性血友病因子(Von Willebrand Factor, vWF)、血栓烷A2、二磷酸腺苷、凝血酶等物质被证实参与血小板的活化、聚集和粘附过程，活化的血小板继续聚集更多的血小板以参与血栓形成过程，从而使血管缓慢阻塞形成动脉血栓。血小板表面糖蛋白IIb/IIIa (GlycoproteinIIb/IIIa, GP IIb/IIIa)整合素位于血小板的表面，纤维蛋白原与血小板结合依赖于GP IIb/IIIa复合物。当促进血小板活化因素激活GP IIb/IIIa后，活化的血小板能与vWF和纤维蛋白结合。因此，GP IIb/IIIa被认为是血栓检测和治疗的潜在靶点 [<xref ref-type="bibr" rid="hanspub.38505-ref3">3</xref>]。</p><p>动脉血栓的另一个来源是心房颤动产生的血栓，研究表明房室颤动可引起内皮损伤，促进释放vWF、组织因子、纤维蛋白原等物质, VWF激活血小板释放促凝因子，促进凝血，导致血栓形成。房颤导致血管内皮分泌的抗凝因子减少，钠尿肽分泌增加，同时房颤会减慢患者血液流动速度，使血小板易于聚集粘附，最终可以引起左心房血栓 [<xref ref-type="bibr" rid="hanspub.38505-ref4">4</xref>]。</p><p>静脉血栓形成原因是血管内皮损伤，血流状态改变和血液的成分异常。当血流速度缓慢，血小板在血管损伤处凝结，促进凝血，血栓由纤维蛋白网罗红细胞持续聚集而成。现有研究表明，P-选择素、溶酶体颗粒糖蛋白(CD63)、溶血酶、促凝血磷脂、D-二聚体等物质在静脉血栓形成中占有重要地位。研究表明人活化凝血因子XIII (Factor XIIIa：FXIIIa) 可以包裹红细胞促进静脉血栓形成 [<xref ref-type="bibr" rid="hanspub.38505-ref5">5</xref>]，FXIII因此被认为是限制静脉血栓形成和治疗静脉血栓的潜在靶点。</p></sec><sec id="s7"><title>3. 现有的检测动脉血栓和静脉血栓方法及其优缺点</title><sec id="s7_1"><title>3.1. 血清学检测</title><p>目前该类方法主要用于诊断血栓形成的辅助诊断。</p><sec id="s7_1_1"><title>3.1.1. D-二聚体</title><p>在血栓形成的同时由于纤溶系统被激活，纤维蛋白复合物降解可使血液中的D-二聚体浓度升高，故通过D-二聚体抗体检测出的体内D-二聚体浓度可作为判断体内血栓形成的依据。该方法敏感性高、简便、无创，但特异性低，例如术后患者、孕妇体内D-二聚体浓度也会增加 [<xref ref-type="bibr" rid="hanspub.38505-ref6">6</xref>]。</p></sec><sec id="s7_1_2"><title>3.1.2. P-选择素</title><p>细胞活化过程中，血小板颗粒膜或内皮细胞中的P-选择素被激活到细胞表面，并以可溶形式释放入血液 [<xref ref-type="bibr" rid="hanspub.38505-ref7">7</xref>]，通过酶联免疫吸附测定(enzyme linked immunosorbent assay: ELISA)方法检测血液中P-选择素浓度可用于检测血栓的形成。</p></sec><sec id="s7_1_3"><title>3.1.3. 其他</title><p>在DVT形成时会有众多物质参与启动一系列炎症反应。这些物质的含量改变或可作为判断血栓形成的依据。这些改变包括血液中蛋白S含量降低，血管细胞粘附分子1、基质金属蛋白酶8、肝细胞生长因子、降钙素原和二甲基精氨酸含量升高，但其特异性不高，且实用性仍需进一步证实 [<xref ref-type="bibr" rid="hanspub.38505-ref8">8</xref>]。</p></sec></sec><sec id="s7_2"><title>3.2. 影像学检测</title><p>目前临床常用的血栓检测方法有多普勒超声、电子计算机断层扫描(Computed Tomography: CT)、磁共振成像(Magnetic Resonance Imaging: MRI)和动静脉造影等, 但这些方法均不能直接检测血栓本身大小。此外，尚有其他方法如电阻抗图谱(Electrical Impedance Spectroscopy: EIS)等正在研发。</p><sec id="s7_2_1"><title>3.2.1. 多普勒成像</title><p>多普勒超声成像是血栓性疾病的首选检测手段，其快速、简便和便宜，但不能区分空气栓子与血栓 [<xref ref-type="bibr" rid="hanspub.38505-ref9">9</xref>]。</p><p>1) 彩色多普勒超声成像</p><p>该方法通过检测血管腔不能被压瘪、有实性回声，血流信号充盈缺损、血流频谱失去期相性改变等现象以检测血栓，操作简单、非侵入性、无辐射、敏感性和特异性高，可实时监测血栓，是深静脉血栓形成的首选检测技术，被期望能在检测血栓的同时检测出血栓形成的病因，但多普勒超声的穿透力差 [<xref ref-type="bibr" rid="hanspub.38505-ref10">10</xref>]，易导致继发性栓塞。</p><p>2) 超显微血管成像(Superb Microvascular Imaging: SMI)</p><p>该方法利用独特算法，通过减少组织运动分析的杂波信号来减少运动伪影，从而可视化有血栓形成的血管内的低速血流。其通过对血栓及周围低速血流的回声对比以检测血栓的形成，是一种新型多普勒超声技术，成像较普通B超和彩色多普勒清晰 [<xref ref-type="bibr" rid="hanspub.38505-ref11">11</xref>]。</p></sec><sec id="s7_2_2"><title>3.2.2. CT成像</title><p>CT成像依靠血栓和周围组织的密度不同，从不同角度进行x射线连续拍摄，通过计算机算法组合获得图像。该方法简便快捷，应用广，其密度值可提示一定的血栓特性和成分信息，但敏感性低，不能用于急性血栓疾病，检测准确度依赖于成像的切片厚度 [<xref ref-type="bibr" rid="hanspub.38505-ref12">12</xref>]。</p></sec><sec id="s7_2_3"><title>3.2.3. MRI</title><p>MRI通过体内不同组分的氢质子在外加磁场特定射频脉冲下的不同物质弛豫时间来识别血栓，分辨率高，无需造影剂，无创，但耗时长，易受运动伪影、金属物质干扰，故不适用于疑为急性血栓栓塞、躁动不安、体内有金属物质植入等的被检测者。其衍生方法分子磁共振和体内直接血栓成像(Direct Thrombus Imaging in vivo: DTI)可提供血栓位置，组成成分和生理功能的直接信息 [<xref ref-type="bibr" rid="hanspub.38505-ref6">6</xref>]。</p></sec><sec id="s7_2_4"><title>3.2.4. 荧光发射计算机断层扫描(Three-Dimensional Fluorescence Emission Computed Tomography: FLECT)</title><p>该方法通过检测血栓分子探针上荧光分子的荧光分布来检测血栓形成。其能三维重建血栓分布，避免电离辐射和过度噪声，成本低，灵敏度高，但目前还只用于实验室研究 [<xref ref-type="bibr" rid="hanspub.38505-ref13">13</xref>]。</p></sec><sec id="s7_2_5"><title>3.2.5. 可见光和近红外学(Near Infrared Spectroscopy: NIRs)成像</title><p>纤维蛋白引起的可见光和近红外光散射程度较红细胞内血红蛋白低，而且流动的血液带走纤维蛋白网中的红细胞，导致红细胞浓度在纤维蛋白网中较外周血液低，故通过检测散射光可以评价血栓形成。该方法即时、无射线辐射危险、能检测到微小血栓，但目前还只用于实验室研究 [<xref ref-type="bibr" rid="hanspub.38505-ref14">14</xref>]。</p></sec></sec><sec id="s7_3"><title>3.3. 其他检测方法</title><sec id="s7_3_1"><title>3.3.1. 磁性纳米颗粒布朗运动(Spectroscopy of Magnetic Nanoparticle Brownian Motion: MSB)</title><p>功能化氧化的铁磁性纳米颗粒与血栓中的凝血酶结合后因布朗运动会产生磁效应，进一步导致弛豫时间缩短的现象的出现。动物实验显示扫描电镜可通过检测这一现象来表征血栓。此外，因为旧血栓表面的凝血酶密度和孔隙率较新鲜血栓低，能结合的磁性纳米颗粒较少，弛豫时间缩短较少，所以该方法可用于区分新旧血栓。但目前该方法仍需要更多的小鼠体内实验证实其有效性 [<xref ref-type="bibr" rid="hanspub.38505-ref15">15</xref>]。</p></sec><sec id="s7_3_2"><title>3.3.2. 电阻层析成像(Electrical Resistance Tomography: ERT)</title><p>本方法基于血流中血细胞浓度高处电阻率高和特定频率下血栓的介电常数与血栓大小成正比的特点，通过测定不同频率下血管周围组织、血液及血栓电容，计算得知血栓的介电常数，获得不同频率的血栓分布图，并其重建为一个单层析图像，从而可视化血栓的形成和位置。该方法能实时监测血栓形成的时间和大小，但分辨率低，难检测小血栓，还未用于临床 [<xref ref-type="bibr" rid="hanspub.38505-ref9">9</xref>]。</p></sec><sec id="s7_3_3"><title>3.3.3. 电阻抗图谱(Electrical Impedance Spectroscopy: EIS)</title><p>在EIS可以很好地区分细胞和蛋白质的特性的基础上，本方法通过利用对组织具有超强穿透力的高频信号测定血液中纤维蛋白的含量，计算(j2πfAε *blood/L) − 1(修正的Hanai方程)的值，以预测血栓的形成。该方法无创，可用于实时监测，但目前尚处于实验阶段 [<xref ref-type="bibr" rid="hanspub.38505-ref16">16</xref>]。</p></sec></sec></sec><sec id="s8"><title>4. 区别动脉血栓和静脉血栓的影像学方法</title><p>通过以上方法可以检测血栓，通过影像学，医生可根据解剖学的特点给血栓定位，但无法确定血栓是动脉起源的还是静脉起源，例如房颤所致的动脉血栓，大多栓塞在静脉系统。如何判断血栓来源是临床工作面临的难题。</p><sec id="s8_1"><title>4.1. 光学相干断层成像技术(Optical Coherence Tomograph: OCT)</title><p>OCT利用近红外光及光学干涉原理成像(光遇到红细胞血浆和红细胞时有不同折射率)检测血栓，其分辨率高、特异性高、成像迅速、能提供血管三维图像，但必须在无血流时进行检测 [<xref ref-type="bibr" rid="hanspub.38505-ref17">17</xref>]。因为动脉血栓(富含血小板)较静脉血栓(富含红细胞)光衰减强，反光信号低，且其图像可伴无信号尾影，故该方法可区别动静脉血栓。但OCT组织穿透力较差，操作繁琐，价格昂贵，不适用于左主干、大血管近端病变检查。</p><p>其衍生方法——频域相关断层扫描(Frequency Domain Optical Coherence Tomography: FD-OCT)在体内成像迅速，分辨率较超声高，但存在因遮蔽而导致的观察偏差，组织穿透力有限致深层组织血栓信号低，图像与病理标本不一致等问题 [<xref ref-type="bibr" rid="hanspub.38505-ref18">18</xref>]。</p></sec><sec id="s8_2"><title>4.2. CT成像</title><p>红细胞使X线衰减增加，而静脉血栓中含有的红细胞较动脉血栓多，故在CT成像中静脉血栓显示高密度影，动脉血栓显示低密度影 [<xref ref-type="bibr" rid="hanspub.38505-ref12">12</xref>]。但由于动脉血栓与周围组织(如血管和脑组织)的密度对比不明显而常常不能与周围组织区分，该方法适用部位少，目前还未用于临床。</p></sec></sec><sec id="s9"><title>5. 靶向血栓的分子影像技术</title><p>靶向血栓的分子影像技术是未来血栓靶向诊断和治疗的发展方向，目前大多数的靶向探针都处于实验阶段。</p><sec id="s9_1"><title>5.1. P-选择素</title><p>岩藻糖胶功能化微泡(Fucoidan-MBs)和EWVDV−Fe−Ink−PFH NPs (perfluorohexane: PFH)是以P-选择素为成像靶标的新型纳米材料。多糖涂层聚氰基丙烯酸异丁酯微泡包裹Fucoidan-MB后可敏感、靶向地在动物模型上检测和溶解血栓，在超声下显示为强回声信号 [<xref ref-type="bibr" rid="hanspub.38505-ref7">7</xref>]。PFH是一种多模态、多功能纳米颗粒，具有靶向性好、穿透力强、操作简单、非侵入性的特点，结合光声成像检测可见血栓部位出现光吸收信号(由于含有光学吸收体Ink和Fe)，结合MR可见血栓处的高T2加权信号出现减低(由于含有Fe，且该物质浓度越高，T2加权信号越低)，结合B超或对比超声可见大鼠体内及体外血栓处存在强回声信号，但其在活体内的代谢过程不清 [<xref ref-type="bibr" rid="hanspub.38505-ref19">19</xref>]。</p></sec><sec id="s9_2"><title>5.2. GP IIb/IIIa</title><p><sup>99m</sup>Tc-apcitide和<sup>99m</sup>Tc-roxififiban以发射γ射线的锝同位素<sup>99m</sup>Tc为标记物，靶向识别大鼠体内静脉血栓中活化血小板表面的GP IIb/IIIa后，结合闪烁γ相机可见闪烁图像上血栓所在位置出现光点。前者对血栓的亲和力和特异性低，后者在体外稳定，与血小板结合紧密并能优先积累于血栓形成处，结合持续时间长，清除迅速，还可抑制血小板聚集及结合纤维蛋白，达60 nM时可抑制血栓形成 [<xref ref-type="bibr" rid="hanspub.38505-ref20">20</xref>]。</p><p>scFv与活化血小板表面GPIIb/IIIa的配体诱导结合位点特异性结合，通过转肽作用构建于蛋白胶束上可形成scFv-LPETG-micelles [<xref ref-type="bibr" rid="hanspub.38505-ref21">21</xref>]。通过流式细胞仪可见有血栓形成的血液中该物质特异性结合的活化血小板检出率较对照组高，且该物质体内循环半衰期长，特异性高，不受阿司匹林等物质影响，其可行性已通过活体显微镜在小鼠体内动脉血栓模型实验中证实；scFv<sub>Targ</sub> (scFv-LPETG) [<xref ref-type="bibr" rid="hanspub.38505-ref13">13</xref>] 与近红外光染色物质 Cy7组成的荧光探针在检测血栓时，FLECT下可定量检测到小鼠体内动脉和静脉血栓处的近红外信号，此探针成本低，灵敏度高；scFv-<sup>64</sup>CuMeCOSar (Cu作为放射性示踪剂) [<xref ref-type="bibr" rid="hanspub.38505-ref22">22</xref>] 在小鼠体内静脉血栓内含有活化血小板的部位表现强荧光，PET/CT可检测到其荧光分布。scFv结合血栓调节蛋白后不仅能定位动静脉血栓，还能抑制血栓形成 [<xref ref-type="bibr" rid="hanspub.38505-ref21">21</xref>]。</p><p>由<sup>18</sup>F标记的elarofiban的衍生物(<sup>18</sup>F-GP1)可特异性结合活化血小板表面的GPIIb/IIIa，结合PET/CT可检测到其大量聚集于人体静脉血栓处而产生的荧光信号。该物质具有良好的药物动力性和安全性，可检测人体急性静脉血栓，有望用于检测下肢远端深部血栓形成并结合P-选择素用于鉴别急慢性静脉血栓 [<xref ref-type="bibr" rid="hanspub.38505-ref23">23</xref>]。</p></sec><sec id="s9_3"><title>5.3. 凝血酶</title><p>TAP-SiO<sub>2</sub>@AuNPs是能靶向结合凝血酶并可被活化凝血酶激活的荧光探针，具有近红外光成像和浓度依赖的X线吸收特性，由硅涂层金纳米颗粒和血栓活化荧光肽TAP组成。由于血栓网状结构能与凝血酶结合，而探针与凝血酶结合后活化凝血酶能降解TAP-SiO<sub>2</sub>@AuNPs而从中裂解出并激活TAP，使得TAP在小鼠动脉血栓内聚集并发光，从而直观地显示血栓形成部位。该方法直观、分辨率高、快速、不完全依赖血栓网状结构进行积聚、可用于NIFR/micro-CT双模态成像 [<xref ref-type="bibr" rid="hanspub.38505-ref24">24</xref>]。</p></sec><sec id="s9_4"><title>5.4. 纤维蛋白</title><p><sup>68</sup>Ga-FBP和<sup>111</sup>In-FBP由放射性标记物<sup>68</sup>Ga-NODAGA和<sup>111</sup>In-DOTA-MA分别与纤维蛋白结合肽结合形成，能靶向血栓中纤维蛋白，从而在血栓中聚集。在PET/SPECT检测下可见大鼠动脉血栓处有高放射信号，且与其背景组织形成强烈信号对比。该两种物质靶向性和稳定性均较好，且检测后清除速度快。此外<sup>64</sup>Cu和Al<sup>18</sup>F也可作为纤维蛋白结合肽放射性标记物用于检测血栓 [<xref ref-type="bibr" rid="hanspub.38505-ref25">25</xref>]。</p><p>Mn-FBP由纤维蛋白结合肽与标记物Mn结合形成，EP-2104R是gadolinium的衍生物，该两种物质均可通过靶向纤维蛋白而定位血栓。该两种物质结合小鼠动脉血栓后，血栓形成部位在磁共振T1加权图像上显示高信号。前者可用于小鼠体内动脉血栓检测，后者可用于人体动脉血栓检测 [<xref ref-type="bibr" rid="hanspub.38505-ref26">26</xref>]。</p><p>大鼠抗小鼠抗体RAM.1. (Rat-Anti-Mouse Antibody: RAM)可靶向结合纤维蛋白，故其与<sup>99m</sup>Tc或[<sup>18</sup>F]FDG标记的肼烟酸结合后形成99mTc/[<sup>18</sup>F]FDG-肼烟酸-RAM.1可通过靶向结合纤维蛋白而定位血栓。在SPECT/CT检测下，可见小鼠体内动脉血栓处有放射性高信号。该物质具有不受其他非特异性抗体影响、对血栓亲和力性高，特异性高、稳定性高、低成本、灵敏性好的特点 [<xref ref-type="bibr" rid="hanspub.38505-ref27">27</xref>]。</p><p>小肽分子GPRPP(Gly-Pro-Arg-Pro-Pro)可以靶向结合纤维蛋白，故其分别与<sup>99m</sup>Tc或<sup>18</sup>F标记的肼烟酸结合后形成的<sup>99m</sup>Tc/[<sup>18</sup>F]FDG-肼烟酸-GPRPP可通过靶向结合纤维蛋白而定位血栓。在SPECT/CT检测下，可见小鼠动脉血栓处有放射性高信号。该物质具有对纤维蛋白亲和力高、血栓吸收度高、在活体内清除迅速的特点。目前，前者的可行性已在小鼠股动脉模型中得到检验，但其对于小血管血栓的检测不灵敏 [<xref ref-type="bibr" rid="hanspub.38505-ref28">28</xref>]；后者已被大鼠颈动脉模型实验证明可行，且其可获得高分辨率小血管血栓图像 [<xref ref-type="bibr" rid="hanspub.38505-ref29">29</xref>]。</p><p><sup>99m</sup>Tc-F4A是由<sup>99m</sup>Tc标记的一种单体双功能四聚体类似物，其由纤维蛋白特异性肽QIWCLGYPCEWQ螯合到HHE-DEG上合成，可以靶向结合纤维蛋白，从而定位血栓。在SPECT/CT检测下，可见小鼠动脉血栓及人体外血栓处有放射性高信号。该物质对血栓亲和力高、体内清除迅速，其可行性已经通过小鼠体内和人体外实验证实 [<xref ref-type="bibr" rid="hanspub.38505-ref30">30</xref>]。</p><p>抗纤维蛋白抗体—超声微泡有生物素化抗纤维蛋白抗体结合到靶向超声微泡的脂质外壳上形成，其中抗纤维蛋白抗体可靶向结合纤维蛋白，故该物质可靶向血栓。在超声检测下可见血栓处有显著增强的回声信号，故可以提高超声检测血栓的敏感性和特异性，也可用于实时监测血栓 [<xref ref-type="bibr" rid="hanspub.38505-ref31">31</xref>]。</p></sec><sec id="s9_5"><title>5.5. 炎性细胞</title><p>静脉血栓形成过程中伴随一系列炎性反应，这些反应会增加组织细胞利用葡萄糖使得血栓部位表现出葡萄糖类似物<sup>18</sup>F-FDG高浓聚 [<xref ref-type="bibr" rid="hanspub.38505-ref32">32</xref>]，结合PET/CT检测可见血栓处有强放射信号。该方法对人体DVT具高度特异性，同时能够区分人体内恶性肿瘤血栓与良性DVT。</p></sec><sec id="s9_6"><title>5.6. FXIIIa</title><p>全氟碳纳米乳液(Perfluorocarbon Nanoemulsions: α2<sup>AP</sup>-PFCs)是α2-antiplasmin通过SPIT (Sterol-based Postinsertion Technique)与<sup>19</sup>F标记的PFCs结合生成。在血栓形成早期α2-antiplasmin能结合FXIIIa，从而靶向定位血栓。由于人体内<sup>19</sup>F含量甚微，故H<sub>1</sub>-MRI检测下血栓处出现高信号，与周围物质产生强烈对比。该物质检测深静脉血栓和肺栓塞时特异性高，敏感度高，对人体细胞(吞噬细胞等)毒性小，目前已成功应用于小鼠体内血栓检测和人类体外血栓检测 [<xref ref-type="bibr" rid="hanspub.38505-ref25">25</xref>]。</p></sec></sec><sec id="s10"><title>6. 展望</title><p>综上所述，在血栓检测的仪器方面，抑制CT和MRI影像的血管搏动伪影干扰等使得血栓检测在影像领域有很大研究空间。在分子探针方面，以GP IIb/IIIa和炎性细胞作为靶点的血栓分子探针在人体内血栓检测实验中取得较好的实验结果，可进一步以更大样本的临床试验验证其在人体内安全性、可行性或进一步研究这些探针在区分急慢性血栓、动静脉血栓等方面的可行性；基于FXIIIa和纤维蛋白的血栓分子探针在检测人体外血栓时可行，且在大鼠体内实验显示出稳定性和安全性，可进一步以小样本人体内实验探讨其在人体内安全性等问题。此外，很对分子探针在动物实验中可靶向检测血栓，但其活体内安全性、稳定性、靶向性、结合效率等问题还在研究中。</p></sec><sec id="s11"><title>基金项目</title><p>国家自然科学基金(81770452)，国家级大学生创新创业训练项目(201910286137)。</p></sec><sec id="s12"><title>文章引用</title><p>陈婉雯,张 玲,姚玉宇. 动静脉血栓检测的检验及影像学研究进展Research Progress of Laboratory and Imaging Detection of Thrombosis[J]. 临床医学进展, 2020, 10(11): 2463-2470. https://doi.org/10.12677/ACM.2020.1011372</p></sec><sec id="s13"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38505-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Lippi, G. and Favaloro, E.J. (2018) Venous and Arterial Thromboses: Two Sides of the Same Coin? Seminars in Thrombosis and Hemostasis, 44, 239-248. https://doi.org/10.1055/s-0037-1607202</mixed-citation></ref><ref id="hanspub.38505-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Kearon, C., Akl, E.A., Ornelas, J., et al. (2016) Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest, 149, 315-352. https://doi.org/10.1016/j.chest.2015.11.026</mixed-citation></ref><ref id="hanspub.38505-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Fiodorenko-dumas, Ż., Dumas, I., Mastej, K., et al. (2019) Receptor GP IIb/IIIa as an Indicator of Risk in Vascular Events. Clinical and Applied Thrombosis/Hemostasis, 25. https://doi.org/10.1177/1076029619845056</mixed-citation></ref><ref id="hanspub.38505-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">杨延宗, 马长生, 高连君, 等. 心房颤动[M]. 北京: 人民卫生出版社, 2017: 384-386.</mixed-citation></ref><ref id="hanspub.38505-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Walton, B.L., Byrnes, J.R. and Wolberg, A.S. (2015) Fibrinogen, Red Blood Cells, and Factor XIII in Venous Thrombosis. Journal of Thrombosis and Haemostasis, 13, S208-S215. https://doi.org/10.1111/jth.12918</mixed-citation></ref><ref id="hanspub.38505-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Van, E.N., et al. (2016) Wells Rule and D-Dimer Testing to Rule out Pulmonary Embolism: A Systematic Review and Individual-Patient Data Meta-Analysis. Annals of Internal Medicine, 165, 253-261. https://doi.org/10.7326/M16-0031</mixed-citation></ref><ref id="hanspub.38505-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Nicoletta, R., Kevin, V., Kieron, H., et al. (2018) Biomarkers for the Diagnosis of Venous Thromboembolism: D-Dimer, Thrombin Generation, Procoagulant Phospholipid and Soluble P-Selectin. Journal of Clinical Pathology, 71, 1015-1022. https://doi.org/10.1136/jclinpath-2018-205293</mixed-citation></ref><ref id="hanspub.38505-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Schaefer, J.K., Jacobs, B., Wakefield, T.W., et al. (2017) New Biomarkers and Imaging Approaches for the Diagnosis of Deep Venous Thrombosis. Current Opinion in Hematology, 24, 274-281.  
https://doi.org/10.1097/MOH.0000000000000339</mixed-citation></ref><ref id="hanspub.38505-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Huu, D.N., Kikuchi, D., Maruyama, O., et al. (2017) Cole-Cole Analysis of Thrombus Formation in an Extracorporeal Blood Flow Circulation Using Electrical Measurement. Flow Measurement and Instrumentation, 53, 172-179.  
https://doi.org/10.1016/j.flowmeasinst.2016.06.025</mixed-citation></ref><ref id="hanspub.38505-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Ozcinar, E., Cakici, M., Dikmen, Y.N., et al. (2017) Thrombus Resolution and Right Ventricular Functional Recovery Using Ultrasound-Accelerated Thrombolysis in Acute Massive and Submassive Pulmonary Embolism. International Angiology, 36, 428-437.</mixed-citation></ref><ref id="hanspub.38505-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Yuta, H., Rie, S., Takahiro, S., et al. (2018) The Utility of Superb Microvascular Imaging for the Detection of Deep Vein Thrombosis. Journal of Medical Ultrasonics, 45, 665-669. https://doi.org/10.1007/s10396-018-0883-0</mixed-citation></ref><ref id="hanspub.38505-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Yusof, N.N.M., Mccann, A., Little, P.J., et al. (2019) Non-Invasive Imaging Techniques for the Differentiation of Acute and Chronic Thrombosis. Thrombosis Research, 177, 161-171. https://doi.org/10.1016/j.thromres.2019.03.009</mixed-citation></ref><ref id="hanspub.38505-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Bock, L., Yu, Y., Alex, L.H., et al. (2017) A Unique Recombinant Fluoroprobe Targeting Activated Platelets Allows in Vivo Detection of Arterial Thrombosis and Pulmonary Embolism Using a Novel Three-Dimensional Fluorescence Emission Computed Tomography (FLECT) Technology. Theranostics, 7, 1047-1061.  
https://doi.org/10.7150/thno.18099</mixed-citation></ref><ref id="hanspub.38505-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Daisuke, S., Tatsuki, F., Katsuhiro, O., et al. (2018) Development of a Real-Time and Quantitative Thrombus Sensor for an Extracorporeal Centrifugal Blood Pump by Near-Infrared Light. Biomedical Optics Express, 9, 190-201.  
https://doi.org/10.1364/BOE.9.000190</mixed-citation></ref><ref id="hanspub.38505-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Hafsa, K., Brent, L.B., et al. (2018) Evaluating Blood Clot Progression Using Magnetic Particle Spectroscopy. Medical Physics, 45, 3258-3264. https://doi.org/10.1002/mp.12983</mixed-citation></ref><ref id="hanspub.38505-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Li, J.P., et al. (2019) Quantitative Detection and Evaluation of Thrombus Formation Based on Electrical Impedance Spectroscopy. Biosensors&amp; Bioelectronics, 141, Article ID: 111437. https://doi.org/10.1016/j.bios.2019.111437</mixed-citation></ref><ref id="hanspub.38505-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Christina, F., Ezin, D., Alexander, S., et al. (2018) An Acoustic Method for Systematic Ventricular Assist Device Thrombus Evaluation with a Novel Artificial Thrombus Model. Journal of Thoracic Disease, 10, S1711-S1719.  
https://doi.org/10.21037/jtd.2018.04.11</mixed-citation></ref><ref id="hanspub.38505-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Yoshitaka, S., Masato, W., Nobuaki, S., et al. (2017) Quantified Coronary Frequency Domain Optical Coherence Tomography Signal Analysis for the Evaluation of Erythrocyte-Rich Thrombus: Ex-Vivo Validation Study. International Journal of Cardiovascular Imaging, 33, 587-594. https://doi.org/10.1007/s10554-016-1038-2</mixed-citation></ref><ref id="hanspub.38505-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Xu, J., et al. (2017) Phase Transition Nanoparticles as Multimodality Contrast Agents for the Detection of Thrombi and for Targeting Thrombolysis: In Vitro and In Vivo Experiments. ACS Applied Materials &amp; Interfaces, 9, 42525-42535. https://doi.org/10.1021/acsami.7b12689</mixed-citation></ref><ref id="hanspub.38505-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">El-kawy, O.A. and Garcıa-horsman, J.A. (2017) 99mTc-Roxififiban: A Potential Molecular Imaging Agent for the Detection and Localization of Acute Venous Thrombosis. Journal of Radioanalytical and Nuclear Chemistry, 311, 1719- 1728. https://doi.org/10.1007/s10967-017-5183-4</mixed-citation></ref><ref id="hanspub.38505-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Wookhyun, K., Carolyn, H., Erbin, D., et al. (2015) Targeted Antithrombotic Protein Micelles. Angewandte Chemie International Edition, 54, 1461-1465. https://doi.org/10.1002/anie.201408529</mixed-citation></ref><ref id="hanspub.38505-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Ziegler, M., Alt, K., Paterson, B.M., et al. (2016) Highly Sensitive Detection of Minimal Cardiac Ischemia Using Positron Emission Tomography Imaging of Activated Platelets. Scientific Reports, 6, Article No. 38161.  
https://doi.org/10.1038/srep38161</mixed-citation></ref><ref id="hanspub.38505-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Chanwoo, K., Jae, S.L., Youngjin, H., et al. (2019) Glycoprotein IIb/IIIa Receptor Imaging with 18F-GP1 PET for Acute Venous Thromboembolism: An Open-Label, Nonrandomized, Phase 1 Study. Journal of Nuclear Medicine, 60, 224-251. https://doi.org/10.2967/jnumed.118.212084</mixed-citation></ref><ref id="hanspub.38505-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Kwon, S.P., Jeon, S., Lee, S.H., et al. (2018) Thrombin-Activatable Fluorescent Peptide Incorporated Gold Nanoparticles for Dual Optical/Computed Tomography Thrombus Imaging. Biomaterials, 150, 125-136.  
https://doi.org/10.1016/j.biomaterials.2017.10.017</mixed-citation></ref><ref id="hanspub.38505-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Bruno, L.O., Francesco, B., Tyson, A.R., et al. (2015) Multimodal Molecular Imaging Reveals High Target Uptake and Specifificity of 111In- and 68Ga-Labeled Fibrin-Binding Probes for Thrombus Detection in Rats. Journal of Nuclear Medicine, 56, 1587-1592. https://doi.org/10.2967/jnumed.115.160754</mixed-citation></ref><ref id="hanspub.38505-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Eric, M.G., Iliyana, P.A., Rancesco, B., et al. (2015) A Manganese Alternative to Gadolinium for MRI Contrast. Journal of the American Oil Chemists Society, 137, 15548-15557. https://doi.org/10.1021/jacs.5b10748</mixed-citation></ref><ref id="hanspub.38505-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Ali, O., Virgile, B., Nicolas, R., et al. (2018) Imaging Thrombosis with 99mTc-Labeled RAM. 1-Antibody In Vivo. Nuclear Medicine and Biology, 61, 21-27. https://doi.org/10.1016/j.nucmedbio.2018.03.003</mixed-citation></ref><ref id="hanspub.38505-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Sedigheh, R., Atefeh, H.B., Abolghasem, M., et al. (2017) Synthesis and Biological Evaluation of Cyclic [99mTc]- HYNIC-CGPRPPC as a Fibrin-Binding Peptide for Molecular Imaging of Thrombosis and Its Comparison with [99mTc]-HYNIC-GPRPP. Molecular Imaging and Biology, 19, 256-264. https://doi.org/10.1007/s11307-016-1004-3</mixed-citation></ref><ref id="hanspub.38505-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Sedigheh, R., Mona, M., Abolghasem, M., et al. (2018) [18F]FDG-Labeled CGPRPPC Peptide Serving as a Small Thrombotic Lesions Probe, Including a Comparison with [99mTc]-Labeled Form. Cancer Biotherapy and Radiopharmaceuticals, 33, 438-445. https://doi.org/10.1089/cbr.2018.2515</mixed-citation></ref><ref id="hanspub.38505-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Grace, C., Walter, J.A., Michael, J.S., et al. (2018) Diagnosis of LVAD Thrombus Using a High-Avidity Fibrin-Specific Tc-99m Probe. Theranostics, 8, 1168-1179. https://doi.org/10.7150/thno.20271</mixed-citation></ref><ref id="hanspub.38505-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Wang, T., Yuan, C., Dai, B., et al. (2017) Click-Chemistry-Mediated Rapid Microbubble Capture for Acute Thrombus Ultrasound Molecular Imaging. Chembiochem, 18, 1364-1368. https://doi.org/10.1002/cbic.201700068</mixed-citation></ref><ref id="hanspub.38505-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Eric, A.O., Chase, W.K., Ahmed, T., et al. (2017) Metabolic and Molecular Imaging of Atherosclerosis and Venous Thromboembolism. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 58, 871-877.  
https://doi.org/10.2967/jnumed.116.182873</mixed-citation></ref></ref-list></back></article>